Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-78c5997874-mlc7c Total loading time: 0 Render date: 2024-11-09T09:27:54.632Z Has data issue: false hasContentIssue false

Chapter 36 - Hematopoietic Cell Transplants for Chronic Myeloid Leukemia: Still a Role for Allogeneic Transplant?

from Section 11 - Hematopoietic Cell Transplants for Myeloproliferative Neoplasms

Published online by Cambridge University Press:  24 May 2017

By
Andrew J. Innes  and
Jane F. Apperley
Edited by
Hillard M. Lazarus ,
Robert Peter Gale ,
Armand Keating ,
Andrea Bacigalupo ,
Reinhold Munker  and
Kerry Atkinson
Edited in association with
Syed Ali Abutalib
Hillard M. Lazarus
Affiliation:
Case Western Reserve University, Ohio
Robert Peter Gale
Affiliation:
Imperial College London
Armand Keating
Affiliation:
University of Toronto
Andrea Bacigalupo
Affiliation:
Ospedale San Martino, Genoa
Reinhold Munker
Affiliation:
Louisiana State University, Shreveport
Kerry Atkinson
Affiliation:
University of Queensland
Syed Ali Abutalib
Affiliation:
Midwestern Regional Medical Center, Cancer Treatment Centers of America, Chicago
Get access
Type
Chapter
Information
Hematopoietic Cell Transplants
Concepts, Controversies and Future Directions
 , pp. 339 - 350
Publisher: Cambridge University Press
Print publication year: 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Fefer, A, Cheever, MA, Thomas, ED, Boyd, C, Ramberg, R, Glucksburg, H, et al. Disappearance of Ph1-positive cells in four patients with chronic granulocytic leukemia after chemotherapy, irradiation and marrow transplantation from an identical twin. N Engl J Med. 1979;300:333–7.CrossRefGoogle ScholarPubMed
Goldman, JM, Apperley, JF, Jones, LM, Marcus, R, Goolden, A, Batchelor, R, et al. Bone marrow transplantation for patients with chronic myeloid leukaemia. N Eng J Med. 1986;314:202–7.CrossRefGoogle Scholar
Goldman, JM, Mackinnon, S. Bone marrow transplantation for chronic myeloid leukaemia using matched unrelated donors. Bone Marrow Transplant. 1989;Suppl 4:38–9.Google ScholarPubMed
Goldman, JM, Majhail, NS, Klein, JP, Wang, Z, Sobocinski, KA, Arora, M, et al Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase. J Clin Oncol. 2010;28:1888–95.CrossRefGoogle ScholarPubMed
Apperley, JF, Jones, L, Hale, G, Waldmann, H, Hows, J, Rombos, Y, et al. Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse. Bone Marrow Transplant. 1986;1:53–66.Google ScholarPubMed
Kolb, HJ, Mittermüller, J, Clemm, C, Holler, E, Ledderose, G, Brehm, G et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990;76:2462–5.CrossRefGoogle ScholarPubMed
Kolb, HJ, Schattenberg, A, Goldman, JM, Hertenstein, B, Jacobsen, N, Arcese, W et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86:2041–50.CrossRefGoogle ScholarPubMed
Or, R, Shapira, MY, Resnick, I, Amar, A, Ackerstein, A, Samuel, S et al. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood. 2003;101:441–5.CrossRefGoogle ScholarPubMed
Crawley, C, Szydlo, R, Lalancette, M, Bacigalupo, A, Lange, A, Brune, M, et al. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood. 2005;106:2969–76.CrossRefGoogle ScholarPubMed
Kebriaei, P, Detry, MA, Giralt, S, Carrasco-Yalan, A, Anagnostopoulos, A, Couriel, D, et al. Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia. Blood. 2007;110:3456–62.CrossRefGoogle ScholarPubMed
Druker, BJ1, Talpaz, M, Resta, DJ, Peng, B, Buchdunger, E, Ford, JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031–7.Google ScholarPubMed
Goldman, JM. Chronic myeloid leukemia: a historical perspective. Semin Hematol. 2010;47: 302–11.CrossRefGoogle ScholarPubMed
Deininger, M, O’Brien, SG, Guilhot, F, Goldman, JM, Hochhaus, A, Hughes, TP et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with imatinib [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114:Abstract 1126.Google Scholar
Sasaki, K, Strom, S, O’Brien, S. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haem. 2015;2:186–93.Google ScholarPubMed
Bower, H, Bjorkholm, M, Dickman, P, Hoglund, M, Lambert, P, Andersson, TML. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. JCO. 2016;34:2851–7.CrossRefGoogle ScholarPubMed
Baccarani, M, Saglio, G, Goldman, J, Hochhaus, A, Simonsson, B, Appelbaum, F, et al. European LeukemiaNet. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108:1809–1820.CrossRefGoogle Scholar
Baccarani, M, Deininger, MW, Rosti, G, Hochhaus, A, Soverini, S, Apperley, JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872–84.CrossRefGoogle Scholar
Hanfstein, B, Müller, MC, Hehlmann, R, Erben, P, Lauseker, M, Fabarius, A, et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia. 2012;26:2096–102.CrossRefGoogle ScholarPubMed
Marin, D, Ibrahim, AR, Lucas, C, Gerrard, G, Wang, L, Szydlo, RM, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol. 2012;30:232–8.CrossRefGoogle ScholarPubMed
Cortes, JE, Hochhaus, A, Kim, D, Shah, NP, Mayer, J, Rowlings, P, et al. Four-year (yr) follow-up of patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) receiving dasatinib or imatinib: efficacy based on early response. Blood (ASH Annual Meeting Abstracts). 2013; 122:Abstract 653.Google Scholar
Saglio, G, Hochhaus, A, Hughes, TP, Clark, RE, Nakamae, H, Kim, D, et al. ENESTnd update: nilotinib (NIL) vs imatinib (IM) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) and the impact of early molecular response (EMR) and Sokal risk at diagnosis on long-term outcomes. Blood (ASH Annual Meeting Abstracts). 2013; 122:Abstract 632.Google Scholar
Brümmendorf, TH, Cortes, JE, de Souza, CA, Guilhot, F, Duvillié, L, Pavlov, D, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial. Br J Haematol. 2014;Sep 8. doi: 10.1111/bjh.13108. [Epub ahead of print]Google ScholarPubMed
Mahon, FX, Réa, D, Guilhot, J, Guilhot, F, Huguet, F, Nicolini, F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11:1029–35.CrossRefGoogle Scholar
Ross, DM, Branford, S, Seymour, JF, Schwarer, AP, Arthur, C, Yeung, DT, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122:515–22.CrossRefGoogle ScholarPubMed
Goldman, J, Gordon, M. Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter? Leuk Lymphoma. 2006;47:1–7.CrossRefGoogle ScholarPubMed
Gratwohl, A, Brand, R, Apperley, J, Crawley, C, Ruutu, T, Corradini, P, et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 2006;91:513–21.Google Scholar
Gratwohl, A, Heim, D. Current role of stem cell transplantation in chronic myeloid leukaemia. Best Pract Res Clin Haematol. 2009;22:431–43.CrossRefGoogle ScholarPubMed
Pavlu, J, Szydlo, RM, Goldman, JM, Apperley, JF. Three decades of transplantation for chronic myeloid leukemia: what have we learned? Blood. 2011;117:755–63.CrossRefGoogle ScholarPubMed
Saussele, S, Lauseker, M, Gratwohl, A, Beelen, DW, Bunjes, D, Schwerdtfeger, R, et al. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood. 2010;115:1880–5.CrossRefGoogle ScholarPubMed
Soverini, S, Hochhaus, A, Nicolini, FE, Gruber, F, Lange, T, Saglio, G, et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood. 2011;118:1208–15.Google Scholar
Ernst, T, La Rosée, P, Müller, MC, Hochhaus, A. BCR-ABL mutations in chronic myeloid leukemia. Hematol Oncol Clin North Am. 2011;25:997–1008.CrossRefGoogle ScholarPubMed
Nicolini, FE1, Basak, GW, Soverini, S, Martinelli, G, Mauro, MJ, Müller, MC, et al. Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. Blood. 2011;118:5697–700.CrossRefGoogle ScholarPubMed
Cortes, JE, Kim, DW, Pinilla-Ibarz, J, le Coutre, P, Paquette, R, Chuah, C, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369:1783–96.CrossRefGoogle ScholarPubMed
Shah, NP, Guilhot, F, Cortes, JE, Schiffer, CA, le Coutre, P, Brümmendorf, TH, et al. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood. 2014;123:2317–24.CrossRefGoogle ScholarPubMed
Giles, FJ, le Coutre, PD, Pinilla-Ibarz, J, Larson, RA, Gattermann, N, Ottmann, OG et al. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia. 2013;27:107–12.CrossRefGoogle ScholarPubMed
Kim, DD, Lee, H, Kamel-Reid, S, Lipton, JH. BCR-ABL1 transcript at 3 months predicts long-term outcomes following second generation tyrosine kinase inhibitor therapy in the patients with chronic myeloid leukaemia in chronic phase who failed Imatinib. Br J Haematol. 2013;160:630–9.CrossRefGoogle Scholar
Sokal, JE, Cox, EB, Baccarani, M, Tura, S, Gomez, GA, Robertson, JE, et al. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood. 1984;63:789–99.CrossRefGoogle ScholarPubMed
Pemmaraju, N, Kantarjian, H, Shan, J, Jabbour, E, Quintas-Cardama, A, Verstovsek, S, et al. Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy. Haematologica. 2012;97:1029–35.CrossRefGoogle Scholar
Kalmanti, L, Saussele, S, Lauseker, M, Proetel, U, Müller, MC, Hanfstein, B, et al. Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV. Ann Hematol. 2014;93:71–80.CrossRefGoogle ScholarPubMed
Hehlmann, R. How I treat CML blast crisis. Blood. 2012;120:737–47.CrossRefGoogle Scholar
Jiang, H, Xu, LP, Liu, DH, Liu, KY, Chen, SS, Jiang, B, et al. Allogeneic hematopoietic SCT in combination with tyrosine kinase inhibitor treatment compared with TKI treatment alone in CML blast crisis. Bone Marrow Transplant. 2014;49:1146–54.CrossRefGoogle ScholarPubMed
Khoury, HJ, Kukreja, M, Goldman, JM, Wang, T, Halter, J, Arora, M, et al. Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis. Bone Marrow Transplant. 2012;47:810–6.CrossRefGoogle Scholar
Kantarjian, HM, Cortes, J, OíBrien, S, Giles, FJ, Albitar, M, Rios, MB et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood. 2002;99:3547–53.CrossRefGoogle ScholarPubMed
Fruehauf, S, Topaly, J, Buss, EC, et al. Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis. Cancer. 2007;109:1543–9.CrossRefGoogle ScholarPubMed
Oki, Y, Kantarjian, HM, Gharibyan, V, et al. Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cancer. 2007;109:899–906.CrossRefGoogle ScholarPubMed
Milojkovic, D, Ibrahim, A, Reid, A, Foroni, L, Apperley, J, Marin, D. Efficacy of combining dasatinib and FLAG-IDA for patients with chronic myeloid leukemia in blastic transformation. Haematologica. 2012;97:473–4.CrossRefGoogle ScholarPubMed
Hochhaus, A, Giles, F, Apperley, J, Ossenkoppele, G, Wang, J , Gallagher, NJ, et al. Nilotinib in chronic myeloid leukemia patients in accelerated phase (cml-ap) with imatinib resistance or intolerance: 24-month follow-up results of a phase 2 study. Haematologica 2009;94(Suppl 2):256 (abstract 0631).Google Scholar
Jiang, Q, Xu, LP, Liu, DH, Liu, KY, Chen, SS, Jiang, B, et al Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase. Blood. 2011;117:3032–40.CrossRefGoogle ScholarPubMed
Ohanian, M, Kantarjian, HM, Quintas-Cardama, A, Jabbour, E, Abruzzo, L, Verstovsek, S, et al. Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase. Clin Lymphoma Myeloma Leuk. 2014;14:155–62.CrossRefGoogle ScholarPubMed
Gratwohl, A, Hermans, J, Goldman, JM, Arcese, W, Carreras, E, Devergie, A, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet. 1998;352:1087–92.CrossRefGoogle ScholarPubMed
Gratwohl, A, Stern, M, Brand, R, Apperley, J, Baldomero, H, de Witte, T, et al. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer. 2009;115:4715–26.CrossRefGoogle ScholarPubMed
Milojkovic, D,Szydlo, D, Hoek, J, Beelen, D, Hamladji, R, Kyrcz-Krzemien, S, et al. Prognostic significance of EBMT score for chronic myeloid leukaemia patients in the era of tyrosine kinase inhibitor therapy: a retrospective study from the chronic malignancy working party of the european group for blood and marrow transplantation (EBMT). Bone Marrow Transplant. 2014;49:S34–5.Google Scholar
Sorror, ML, Maris, MB, Storb, R, Baron, F, Sandmaier, BM, Maloney, DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005;106:2912–9.CrossRefGoogle ScholarPubMed
Sorror, M, Storer, B, Sandmaier, BM, Maloney, DG, Chauncey, TR, Langston, A, et al. Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer. 2008;112:1992–2001.CrossRefGoogle ScholarPubMed
Zipperer, E, Pelz, D, Nachtkamp, K, Kuendgen, A, Strupp, C, Gattermann, N, et al. The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome. Haematologica. 2009;94:729–32.CrossRefGoogle ScholarPubMed
Pavlů, J, Kew, AK, Taylor-Roberts, B, Auner, HW, Marin, D, Olavarria, E et al.Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase. Blood. 2010;115:4018–20.CrossRefGoogle ScholarPubMed
Zaucha, JM, Prejzner, W, Giebel, S, Gooley, TA, Szatkowski, D, Kałwak, K, et al. Imatinib therapy prior to myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant. 2005;36:417–24.CrossRefGoogle ScholarPubMed
Deininger, M, Schleuning, M, Greinix, H, Sayer, HG, Fischer, T, Martinez, J, et al. The effect of prior exposure to imatinib on transplant-related mortality. Haematologica. 2006;91:452–9.Google ScholarPubMed
Lee, SJ, Kukreja, M, Wang, T, Giralt, SA, Szer, J, Arora, M, et al. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood. 2008;112:3500–7.Google ScholarPubMed
Warlick, E, Ahn, KW, Pedersen, TL, Artz, A, de Lima, M, Pulsipher, M, et al. Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era. Blood. 2012;119:4083–90.CrossRefGoogle ScholarPubMed
Uzunel, M, Mattsson, J, Brune, M, Johansson, JE, Aschan, J, Ringdén, O.et al. Kinetics of minimal residual disease and chimerism in patients with chronic myeloid leukemia after nonmyeloablative conditioning and allogeneic stem cell transplantation. Blood. 2003;101:469–72.CrossRefGoogle ScholarPubMed
Anasetti, C, Logan, BR, Lee, SJ, Waller, EK, Weisdorf, DJ, Wingard, JR, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med. 2012;367:1487–96.CrossRefGoogle ScholarPubMed
Krejci, M, Mayer, J, Doubek, M, Brychtova, Y, Pospisil, Z, Racil, Z, et al. Clinical outcomes and direct hospital costs of reduced-intensity allogeneic transplantation in chronic myeloid leukemia. Bone Marrow Transplant. 2006;38:483–91.CrossRefGoogle ScholarPubMed
Basak, GW, de Wreede, LC, van Biezen, A, Wiktor-Jedrzejczak, W, Halaburda, K, Schmid, C et al. Donor lymphocyte infusions for the treatment of chronic myeloid leukemia relapse following peripheral blood or bone marrow stem cell transplantation. Bone Marrow Transplant. 2013;48:837–42.CrossRefGoogle ScholarPubMed
Eapen, M, Logan, BR, Appelbaum, F, Antin, A, Anasetti, C, Couriel, DR, et al. Long-term survival after transplantation of unrelated donor peripheral blood or bone marrow hematopoietic cells for hematologic malignancy. Biol Blood Marrow Transplant. 2015;21:55–9.CrossRefGoogle ScholarPubMed
Sehn, LH1, Alyea, EP, Weller, E, Canning, C, Lee, S, Ritz, J, et al. Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: impact of donor lymphocyte infusion. J Clin Oncol. 1999;17:561–8.CrossRefGoogle ScholarPubMed
Socié, G, Schmoor, C, Bethge, WA, Ottinger, HD, Stelljes, M, Zander, AR, et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood. 2011;117:6375–82.CrossRefGoogle ScholarPubMed
Lin, F, van Rhee, F, Goldman, JM, Cross, NC. Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation. Blood. 1996;87:4473–8.CrossRefGoogle ScholarPubMed
Krejci, M, Mayer, J, Doubek, M, Brychtova, Y, Pospisil, Z, Racil, Z, et al. Clinical outcomes and direct hospital costs of reduced-intensity allogeneic transplantation in chronic myeloid leukemia. Bone Marrow Transplant. 2006;38:483–91.CrossRefGoogle ScholarPubMed
Dazzi, F, Szydlo, RM, Craddock, C, Cross, NC, Kaeda, J, Chase, A, et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood. 2000;95:67–71.CrossRefGoogle ScholarPubMed
Innes, AJ, Beattie, R, Sergeant, R, Damaj, G, Foroni, L, Marin, D, et al. Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT. Bone Marrow Transplant. 2013;48:1324–8.CrossRefGoogle ScholarPubMed
Innes, AJ, Lurkins, J, Szydlo, R, Guerra, A, Milojkovic, D, Pavlu, J et al. The majority of patients receiving donor lymphocyte infusions for relapsed chronic myeloid leukemia remain PCR positive despite maintaining long-term remission. Blood. 2011:118: Abstract 4103.CrossRefGoogle Scholar
Zeidner, JF1, Zahurak, M, Rosner, GL, Gocke, CD, Jones, RJ, Smith, BD. The evolution of treatment strategies for patients with chronic myeloid leukemia relapsing after allogeneic bone marrow transplant: can tyrosine kinase inhibitors replace donor lymphocyte infusions? Leuk Lymphoma. 2015;56:128–34.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×